Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01324323 · ClinicalTrials.gov registry record · Phase 1
Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01324323 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 14 participants.
The verdict
NCT01324323, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect and safety of multiple doses of rifampin on the pharmacokinetics of romidepsin after a single intravenous (IV) infusion.
Interventions
- DRUG Rifampin
- DRUG Romidepsin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-04-01 |
| Est. Completion | 2012-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01324323
The ClinicalTrials.gov registry entry for NCT01324323 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rifampin is the first listed.
NCT01324323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01324323 about?
NCT01324323 is a clinical study titled "Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer". The purpose of this study is to evaluate the effect and safety of multiple doses of rifampin on the pharmacokinetics of romidepsin after a single intravenous (IV) infusion.
What is the current status of trial NCT01324323?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2011-04-01. Estimated completion is 2012-03-01.
What interventions are being tested in trial NCT01324323?
The interventions under investigation include: Rifampin (DRUG), Romidepsin (DRUG).
Who is sponsoring clinical trial NCT01324323?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.